GB202206151D0 - Novel formulation - Google Patents

Novel formulation

Info

Publication number: GB202206151D0
Authority: GB; United Kingdom
Prior art keywords: novel formulation; formulation; novel
Prior art date: 2022-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB2206151.9A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Reckitt Benckiser Health Ltd

Original Assignee

Reckitt Benckiser Health Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2022-04-27

Filing date

2022-04-27

Publication date

2022-06-08

2022-04-27 Application filed by Reckitt Benckiser Health Ltd filed Critical Reckitt Benckiser Health Ltd

2022-04-27 Priority to GBGB2206151.9A priority Critical patent/GB202206151D0/en

2022-06-08 Publication of GB202206151D0 publication Critical patent/GB202206151D0/en

Status Ceased legal-status Critical Current

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
GBGB2206151.9A GB202206151D0 (en)	2022-04-27	2022-04-27	Novel formulation

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB2206151.9A GB202206151D0 (en)	2022-04-27	2022-04-27	Novel formulation

Publications (1)

Publication Number	Publication Date
GB202206151D0 true GB202206151D0 (en)	2022-06-08

Family

ID=81851965

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB2206151.9A Ceased GB202206151D0 (en)	2022-04-27	2022-04-27	Novel formulation

Country Status (1)

Country	Link
GB (1)	GB202206151D0 (en)

2022
- 2022-04-27 GB GBGB2206151.9A patent/GB202206151D0/en not_active Ceased

Similar Documents

Publication	Publication Date	Title
IL319149A (en)	2025-04-01	Upadacitinib formulation
GB202007546D0 (en)	2020-07-01	Formulation
IL307849A (en)	2023-12-01	Sotorasib formulation
GB202204171D0 (en)	2022-05-11	Novel formulations
GB202102636D0 (en)	2021-04-07	Formulation
GB202211231D0 (en)	2022-09-14	Novel formulation
GB202206151D0 (en)	2022-06-08	Novel formulation
GB202318884D0 (en)	2024-01-24	Formulation
GB202316857D0 (en)	2023-12-20	Cannabinoid-based formulation
GB202312814D0 (en)	2023-10-04	Formulation
GB202312220D0 (en)	2023-09-20	Formulation
GB202311622D0 (en)	2023-09-13	Formulation
GB202311439D0 (en)	2023-09-06	Formulation
IL317857A (en)	2025-02-01	Orellanine formulation
GB202308224D0 (en)	2023-07-19	Formulation
GB202306995D0 (en)	2023-06-28	Cannabinoid-based formulation
GB202307003D0 (en)	2023-06-28	Cannabinoid-based formulation
GB202306990D0 (en)	2023-06-28	Cannabinoid-based formulation
GB202307002D0 (en)	2023-06-28	Cannabinoid-based formulation
GB202303663D0 (en)	2023-04-26	Aerosolisable formulation
GB202218160D0 (en)	2023-01-18	Formulation
GB202217857D0 (en)	2023-01-11	Formulation
GB202217267D0 (en)	2023-01-04	Aerosolisable formulation
GB202217148D0 (en)	2022-12-28	Formulation
GB202216335D0 (en)	2022-12-21	Formulation

Legal Events

Date	Code	Title	Description
2023-05-10	AT	Applications terminated before publication under section 16(1)